## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.08 indicates fundamental undervaluation. Quality metrics strong (ROE 62%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($109.38)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. DaVita stock under the microscope: cautious optimism meets reimbursement risk**
- Source: AD HOC NEWS | 20260103T070841 | Neutral | Relevance: 100%
- DaVita's stock has seen a solid uptrend over recent months, driven by both market optimism and successful cost controls, making it an impressive performer in the defensive healthcare sector despite its ties to government reimbursement. However, the company faces ongoing challenges from U.S. healthcare policy, payer mix complexities, and the constant threat of regulatory changes impacting reimbursement. Its future performance depends on supportive reimbursement policies, sustained operating margins amid wage pressures, and the success of its risk-bearing contracts and coordinated kidney care initiatives.

**2. Rockwell Medical extends DaVita supply agreement with price adjustment By Investing.com**
- Source: Investing.com South Africa | 20260105T120810 | Somewhat-Bullish | Relevance: 95%
- Rockwell Medical (NASDAQ:RMTI) announced a one-year extension to its supply agreement with DaVita, Inc., effective through December 31, 2026. The amendment includes a price increase for products supplied by Rockwell Medical, which maintains a strong liquidity position. This agreement comes after Rockwell Medical reported Q3 2025 earnings slightly below forecasts and a recent change in its Board of Directors.

**3. Rockwell Medical Extends DaVita Supply Agreement with Price Increase**
- Source: TipRanks | 20260105T120234 | Somewhat-Bullish | Relevance: 92%
- Rockwell Medical (RMTI) has extended its product purchase agreement with DaVita Inc. by one year, now running until December 31, 2026. The amended contract also includes a price increase on products, which is expected to boost Rockwell Medical's revenue and strengthen its relationship with DaVita. Despite this positive development, TipRanks' AI Analyst, Spark, rates RMTI as "Neutral" due to weak financial performance, valuation concerns, and bearish technical momentum.

**4. Rockwell Medical extends DaVita supply agreement with price adjustment By Investing.com**
- Source: Investing.com India | 20260105T120234 | Somewhat-Bullish | Relevance: 87%
- Rockwell Medical (NASDAQ:RMTI) announced an extension of its supply agreement with DaVita Inc. until December 31, 2026, which includes a price adjustment for its products. This micro-cap company, with a market capitalization of $34 million, maintains a strong liquidity position and holds more cash than debt. The extension and price increase were confirmed following Rockwell Medical's Q3 2025 earnings report and an SEC filing.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($54.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $55M sold (3 transactions in 90 days).
2. High short interest (21.1%, 7.3 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 14.9% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.08 suggests fair value with growth premium. Forward P/E 8.9x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($55.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.1B |
| Beta | 0.99 |
| 52W Range | $112.54 - $179.60 |
| Short Interest | 21.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.08 |
| Forward P/E | 8.9 |
| Current P/E | 10.7 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.6% to -2.3% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Below SMA200 (0.85x), long-term trend not supportive. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.27% (CS: 17) | Weak |
| RSI_14 | 38.6 | Neutral |
| MACD Histogram | -0.10 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.955x | Below |
| vs SMA200 | 0.851x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $113.94
- **Stop Loss:** $109.38 (4.0% risk)
- **Target:** $123.06 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 189
- **Position Value:** $21,534.66
- **Portfolio %:** 21.53%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*